Advancing Drug Delivery for Parenteral Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advancing Drug Delivery for Parenteral Applications

Pharmaceutical Technology
Volume 37, Issue 5, pp. s33

Drug delivery is a multidisciplinary field. Researchers recently developed a drug-delivery system to mitigate some problems associated with jet-injection drug delivery, and also improved on the design and operation of microscale actuators as a possible drug-delivery method.

Researchers at the Massachusetts Institute of Technology (MIT) recently developed a jet-injection drug-delivery system based on a custom high-stroke Lorentz-force motor to mitigate some of the problems typically associated with controlling drug delivery through jet injection. The researchers noted that needle-free drug delivery by jet injection typically is achieved by ejecting a liquid drug through a narrow orifice at high pressure, thereby creating a fine high-speed fluid jet that can readily penetrate skin and tissue. The researchers assert that such injection systems use force- and pressure-generating principles that cause injection in an uncontrolled manner with limited ability to regulate delivery volume and injection depth. To address these shortcomings, the researchers developed a controllable jet injection device, based on a custom high-stroke linear Lorentz-force motor that is feed-back controlled during the time-course of an injection (1).

The key part of the design is the Lorentz-force actuator, a magnet surrounded by a coil of wire that is attached to a piston inside a drug ampul, according to a May 24, 2012 MIT press release. When a current is applied, it interacts with the magnetic field to produce a force that pushes the piston forward, ejecting the drug at very high pressure and velocity out through the ampul’s nozzle. The speed of the coil and the velocity can be controlled by the amount of current applied. The resulting waveforms generally consist of two distinct phases: an initial high-pressure phase in which the device ejects drug at a high-enough velocity to breach the skin and reach the desired depth, then a lower-pressure phase where drug is delivered in a slower stream that can easily be absorbed by the surrounding tissue, according to the MIT press release. Through testing, the group found that various skin types may require different waveforms to deliver adequate volumes of drugs to the desired depth (1).

The team is also developing a version of the device for transdermal delivery of drugs ordinarily found in powdered form by programming the device to vibrate, turning powder into a fluidized form that can be delivered through the skin much like a liquid, according to MIT release. Such a powder-delivery vehicle may help mitigate the problems associated with needing a cold-chain system for delivering vaccines and other biopharmaceuticals.

In another development, researchers at the US Department of Energy (DOE)’s Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley, have developed an new microscale actuator based on an vanadium dioxide that expands and contracts in response to a small temperature variation and which show promise for drug delivery among other applications.

Piezoelectric actuators are the industry-standard for mechanical actuation on micro scales, but they are complicated to grow, need large voltages for small displacements, and typically involve toxic materials such as lead, according to a Dec. 2012 Berkeley Lab press release. The researchers’ device is simpler, uses nontoxic materials, and creates a displacement that is larger at a lower driving voltage. It works equally well in water, making it suitable for biological and microfluidic applications. The researchers envision using the microactuators as tiny pumps for drug delivery (2) .

References

1. A. Taberner, N.C. Hogan, and I.W. Hunter, Medical Eng. & Physics, online, DOI/10.1016/j.medengphy.2011.12.010, Jan. 13, 2012.

2. J. Wu, Nano Lett., 12 (12), 6302-6308 (2012).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here